
Cartiva developed the Synthetic Cartilage Implant (SCI), the first and only FDA-approved synthetic cartilage device for treating osteoarthritis of the first metatarsophalangeal (big toe) joint. The SCI is composed of a biocompatible polyvinyl alcohol hydrogel polymer with mechanical properties mimicking natural articular cartilage, implantable in approximately 35 minutes. The company was acquired by Wright Medical Group N.V. in October 2018 for $435 million, and subsequently became part of Stryker following Stryker's acquisition of Wright Medical in 2020.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account